Stockscreener 앱 받기
9.07
12.39%
1.00
시장 영업 전:
8.29
-0.78
-8.60%
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Long-Term Trend Tracking and Signal Summary - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - The Malaysian Reserve
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Barchart.com
What to expect from Capricor Therapeutics Inc. in the next 30 daysPredictive Model for Intraday Swing Forecast - Newser
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm | FinancialContent - FinancialContent
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - cnhinews.com
Capricor Therapeutics Q2 Earnings: Latest Updates on DMD Drug Deramiocel Coming August 13 - Stock Titan
Capricor Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 - Quiver Quantitative
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Popularity With Investors Under Threat As Stock Sinks 25% - 富途牛牛
Sector ETF performance correlation with Capricor Therapeutics Inc.Intraday Signal Forecast for Fast Traders - Newser
Investors in Capricor Therapeutics, Inc. Should Contact The - GlobeNewswire
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER - GlobeNewswire
Capricor Shareholder Sues Board After FDA’s Heart Therapy Spurn - Bloomberg Law News
Investor Alert: Deadline Approaching to Join Capricor Therapeutics, Inc. (CAPR) Class ActionContact Levi & Korsinsky - Newsfile
The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineCAPR - PR Newswire
What high frequency data says about Capricor Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser
Will Capricor Therapeutics Inc. bounce back from current supportAI Volatility Forecast and Risk Monitor - Newser
‘Unprecedented’ FDA Leaks Sow Confusion For Patients, Sarepta and Capricor - BioSpace
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor - GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Enidnews.com
Is it the right time to buy Capricor Therapeutics Inc. stockGet exclusive access to professional stock picks - Jammu Links News
When is Capricor Therapeutics Inc. stock expected to show significant growthUnmatched profit potential - Jammu Links News
Why is Capricor Therapeutics Inc. stock attracting strong analyst attentionRapidly growing investment returns - Jammu Links News
Capricor Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - Jammu Links News
Should I hold or sell Capricor Therapeutics Inc. stock in 2025Market-leading capital gains - Jammu Links News
Bank of New York Mellon Corp Has $832,000 Position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
0.24%
3.39%
자본화:
|
볼륨(24시간):